Is Depression a Side Effect of Finasteride?
Depression is not listed as a documented adverse effect in the major clinical guidelines for finasteride, though decreased libido, erectile dysfunction, and decreased ejaculate volume are well-established side effects. However, emerging research evidence from the past several years suggests a potential association between finasteride use and depression/suicidality that warrants serious consideration when prescribing this medication.
What the Guidelines and FDA Label Say
The 2009 ASCO/AUA clinical practice guideline 1 comprehensively reviewed adverse events from finasteride in large randomized controlled trials and does not mention depression as a recognized side effect. The documented adverse effects include:
- Sexual dysfunction: 2-4% increase in erectile dysfunction, decreased libido, and decreased ejaculate volume compared to placebo
- Gynecomastia: 4.1% vs 2.4% in placebo (statistically significant)
- Endocrine effects: breast tenderness and enlargement
The FDA drug label 2 similarly does not list depression as a side effect in its adverse reactions section. Post-marketing surveillance mentioned hypersensitivity reactions, testicular pain, and male breast cancer, but not psychiatric symptoms.
What Recent Research Evidence Shows
The evidence landscape has changed dramatically since those 2009 guidelines. Multiple recent studies paint a concerning picture:
Studies Supporting an Association:
A 2025 analytical review 3 found that concerns about depression from finasteride were raised as early as 2002, but there has been a two-decade delay in recognition. Between 2017-2023, four independent analyses of adverse event reporting systems and four healthcare database studies indicated significant increases in risk for depression, anxiety, and suicidal behavior with finasteride use.
A 2021 meta-analysis 4 found:
- Pooled rate of depressive symptoms: 3.33% with finasteride vs 2.54% without (p < 0.0001)
- Odds ratio of 2.14 (95% CI: 1.40-3.27) for depression with finasteride
- Risk of suicidal ideation/behavior: 21.2% vs 14.0% (p < 0.0001)
A 2025 FAERS database analysis 5 detected no significant signals from 2006-2011, but found signals during 2013-2018 and 2019-2023. For example, suicidal ideation reporting was significantly elevated (ROR = 2.8 in 2013-2018; ROR = 5.0 in 2019-2023).
A prospective 2006 study 6 of 128 men with androgenetic alopecia found that finasteride treatment significantly increased both Beck Depression Inventory scores (p < 0.001) and HADS depression scores (p = 0.005) after just two months of treatment.
Studies Contradicting the Association:
A 2025 cohort study and Mendelian randomization analysis 7 found no significant association between finasteride use and depression or suicide in the UK Biobank cohort, even after adjusting for covariates.
A 2025 animal study 8 showed that chronic finasteride administration (21 days) in rats did not induce robust depression- or anxiety-like behavior, potentially due to adaptive responses in corticosterone levels.
Clinical Interpretation and Recommendation
The divergence between older guidelines and recent research creates a clinical dilemma, but the weight of recent human evidence—particularly the meta-analysis 4 and multiple pharmacovigilance studies 3, 5—suggests depression and suicidality are real risks that must be discussed with patients.
When Prescribing Finasteride:
You should explicitly counsel patients about the potential for depression and suicidal ideation, even though this is not in the official FDA labeling. Specifically:
- Screen for baseline depression/anxiety before initiating treatment
- Avoid or use extreme caution in patients with current depression, history of depression, or suicidal ideation
- Warn patients that psychiatric symptoms can emerge during treatment and may persist after discontinuation (so-called "post-finasteride syndrome")
- Monitor actively for mood changes, especially in the first 2-6 months of treatment
- Consider the risk-benefit ratio carefully: For androgenetic alopecia (a cosmetic indication), the potential for depression and suicidality may outweigh benefits in many patients
Important Caveats:
The 2009 guidelines 1 noted that sexual dysfunction effects were "smaller than natural sources of variability" (mean difference of 3.21 points on a 0-100 scale). However, this does not apply to depression risk, which was not adequately studied in those trials.
The increase in reported psychiatric adverse events after 2012 5 may reflect increased awareness following recognition of "post-finasteride syndrome," but this does not negate the reality of the symptoms—it likely represents previously under-recognized and under-reported harm.
The precautionary principle applies here: When a medication for a cosmetic indication (hair loss) carries potential risks of depression and suicide, the burden should be on proving safety, not on accumulating more evidence of harm 3.